

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Mathias LOCHER et al.

Art Unit: Not Yet Assigned

Int.'l Appl. No. PCT/EP2003/008607
(Filed August 4, 2003)

Examiner: Not Yet Assigned

Confirmation No. Not Yet Assigned

Filing Date: February 9, 2005

Atty. Docket No. 42804-212835

For: NOVEL COMBINATION OF
GLUCOCORTICOIDS AND PDE-4
INHIBITORS ...

Customer No.

26694

PATENT TRADEMARK OFFICE

Information Disclosure Statement

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply the duty of disclosure pursuant to 37 C.F.R. § 1.56, submitted herewith is a form listing the documents cited in the International Search report of International Application No. PCT/EP2003/008607. The relevance of each document is indicated in the International Search Report.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

If the copies were not furnished and a copy of a cited document is desired, please inform the undersigned and a copy of the missing document will be supplied.

0/523802
DT12 Rec'd PCT/PTO 09 FEB 2005

Applicants: Mathias LOCHER
Attorney's Doc. No.: 42804-212835

In view of the above, no further statement of relevance need be given, and as all requirements of 37 C.F.R. § 1.97 and § 1.98, and all official guidelines pertaining to Information Disclosure Statements have been complied with, it is respectfully requested that the Examiner consider the cited publications and make them of record.

Respectfully submitted,

Date: 2/9/05

C. A. Hobbs
Ann S. Hobbs, Ph.D.
Registration No. 36,830
VENABLE LLP
P.O. Box 34385
Washington, D.C. 20043-9998

Telephone: (202) 344-4000
Telefax: (202) 344-8300

DOCS#613018

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Dr. Mathias LOCHER et al.
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	42804-212835

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6 251 923	06-26-2001	EMMANUEL et al.	
	AB	US-4 996 335	02-26-1991	NICHOLAS	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	DE 199 17 504 A	10-19-2000			
	BB	GB 2 079 755 A	01-27-1982			
	BC	WO 03 039548 A	05-15-2003			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	COMPTON C H et al., "Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study", July 28, 2001, pgs. 265-270, XP004297349, ISSN: 0140-6736.		
	CB	WHITTAKER A J et al., "Inhaled steroid therapy in chronic obstructive pulmonary disease", March 2000, pgs. 104-109, XP009020341, ISSN: 1070-5287.		
	CC	HAMMERBECK D M et al., "Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models", August 2000, pgs. 317-329, XP009020362, ISSN: 0360-3997.		
	CD	TORPHY T J et al., "Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic", England 1999, pgs. 131-135, XP001155797, ISSN: 1094-5539.		
	CE	BARNES P J., "Chronic obstructive pulmonary disease: new opportunities for drug development", October 1998, pgs. 415-423, XP004156947, ISSN: 0165-6147.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

DOCS#612720

Examiner Signature		Date Considered	
--------------------	--	-----------------	--